Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements
China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot...
ADC / XDC
Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with...
Huadong Medicine’s Mirvetuximab Soravtansine Heads for Priority Review by China’s CDE
The China’s Center for Drug Evaluation (CDE) website has indicated that Huadong Medicine Co., Ltd...
Sichuan Biokin Pharmaceutical Gets FDA Approval for BL-B01D1 Clinical Study
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...
Grand Pharmaceutical Initiates Phase I Study for TLX250-CDx in Renal Mass Imaging
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...
Sanyou Biopharmaceuticals and Huadong Medicine Expand Partnership on Macromolecule Therapeutics
China-based Sanyou Biopharmaceuticals Co., Ltd has announced a licensing deal with compatriot firm Huadong Medicine...
Coherent Biopharma and C-Ray Therapeutics Partner to Advance Peptide-Drug Conjugate Development
China-based Coherent Biopharma and C-Ray Therapeutics have announced a strategic partnership to delve into the...
Sichuan Kelun’s SKB264 Earns Breakthrough Therapy Designation for Breast Cancer Treatment
The Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Kelun Pharmaceutical Co.,...
Innovent Biologics and RemeGen Partner on Clinical Study for PD-1 Inhibitor and ADC Drugs
China-based Innovent Biologics Inc., (HKG: 1801) has entered into a clinical study and supply cooperation...
CDE Releases Draft Guidelines for Antibody Drug Conjugate Research and Evaluation
The Center for Drug Evaluation (CDE) has released a draft set of “Guiding Principles for...
Minghui Pharmaceutical Achieves First Dosing Milestone in Phase I Studies for ADC Candidates
China-based biotech Minghui Pharmaceutical Inc. has reported that the first dosing has been completed in...
Dartsbio Pharmaceuticals and SIMM Receive NMPA Approval for ADC DS001 Clinical Trial
Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has partnered with the Shanghai Institute of Materia Medica...
CSPC Pharmaceutical’s CPO301 Earns Fast-Track Status for EGFR Mutant NSCLC Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...
CDE Indicates Priority Review for Overland ADCT’s Zynlonta and BeiGene’s Brukinsa
The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY)...
CSPC Pharmaceutical’s CPO301 Receives Health Canada Approval for Phase I Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...
Adcendo ApS Expands Partnership with Duality Biologics for Two Additional ADCs
Denmark-based Adcendo ApS has announced the expansion and exercise of options to two additional antibody...
Sichuan Kelun Pharmaceutical to Present Clinical Data on RET Inhibitor and ADC at ASCO
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has unveiled plans to...
BioRay Pharmaceutical’s LIV-1 Targeted ADC BRY812 Files IND in China
Shanghai-based BioRay Pharmaceutical Co., Ltd has announced that an investigational new drug (IND) filing has...